Pancreatic Cancer Diagnostic Market Definition
According to the American Cancer Society, around 3 percent of all cancers in the United States are pancreatic cancers. Studies conducted by various institutes showed that 91% of pancreatic cancer patients will die within five years of diagnosis and only 9% will survive more than five years. Pancreatic cancer is a type of cancer in which uncontrolled cell growth begins in a part of the pancreas. The pancreas is an organ in a human abdomen that lies behind the lower part of the stomach. It releases enzymes that aid digestion and produces hormones that help to manage blood sugar. Pancreatic cancer is of two types including endocrine pancreatic cancer and exocrine pancreatic cancer. It is occasionally detected at its early stages when it is most curable because it often doesn’t cause symptoms until after it has spread to other organs. The diagnosis of pancreatic cancer done with the help of laboratory tests, imaging tests, biopsy and assessing cancer symptoms. The treatment options for pancreatic cancer are chosen based on the stage of cancer. It involves surgery, chemotherapy, radiation therapy or a combination of these. According to the Hirshberg Foundation for Pancreatic Cancer Research, pancreatic cancer is the 3rd leading cause of cancer-related death in the United States surpassing breast cancer. It is expected to become the 2nd leading cause of cancer-related death in the United States by the year 2021, surpassing colorectal cancer.
The market study is broken down, by Application (Hospitals, Clinics, Oncology Institutes and Diagnostic Centers) and major geographies with country level splits.
Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Pancreatic Cancer Diagnostic market throughout the predicted period.
Fujifilm Holdings Corporation (Japan), Roche Holding AG (Switzerland), GE Healthcare (United States), Siemens AG (Germany), Becton, Dickinson and Company (United States), Philips Healthcare (Netherlands), Hitachi Medical Corporation (Japan), Danaher Corporation (United States), Abbott Laboratories (United States) and Canon Medical Systems Corporation (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Myriad Genetics, Inc. (United States), Qiagen (Germany), Asuragen, Inc. (United States), Toshiba Medical Systems Corporation (Japan) and Carestream Health (United States).
AdvanceMarketAnalytics has segmented the market of Global Pancreatic Cancer Diagnostic market by Type, Application and Region.
On the basis of geography, the market of Pancreatic Cancer Diagnostic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Cancer Type, the sub-segment i.e. Endocrine Pancreatic Cancer will boost the Pancreatic Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Imaging Tests (CT Scan, MRI, Ultrasound, PET Scan, Angiography and Cholangiopancreatography) will boost the Pancreatic Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
In January 2019, Royal Philips, a global leader in health technology, unveiled its latest Imaging Systems range with solutions including the Next MR Wave, Epiq Elite Ultrasound System, DigitalDiagnost C90( Digital X-ray), Intellispace Discovery, Compressed SENSE and Philips IQon (CT) at IRIA 2019, the annual conference of Indian Radiological and Imaging Association, in Chandigarh.
- Increasing Diagnosed Pancreatic Cancer Cases
- Increase in the Prevalence of Pancreatic Cancer
- Rise in the Cancer Related Deaths Worldwide
- Increased Consumption of Alcohol and Tobacco Products
- Development of Healthcare Infrastructure in Emerging Economies
- Technological Advancements in the Field Of Medical Science
- Huge Investments and Franchising By Major Players
- Difficulty in Early Diagnosis of the Pancreatic Cancer
- High Cost of the Cancer Treatments
- Lack of Awareness about Cancer Symptoms among People
- Low Success Rates of the Clinical Trails
Key Target AudiencePancreatic Cancer Diagnostic Instrument Manufacturers, Research Organization and Associations, Research Professionals, Emerging Companies, Distributors, Government Body & Associations and End-user
About ApproachThe research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase